YPK9 Antibody

What is YPK9 and what cellular functions does it perform?

YPK9/YOR291W encodes a vacuolar membrane protein in Saccharomyces cerevisiae (budding yeast). It functions as a P5-type ATPase with significant similarities to yeast Spf1p, primarily involved in the sequestration of heavy metals within the vacuole. Recent research has expanded our understanding of YPK9's cellular roles beyond metal homeostasis, revealing its critical involvement in oxidative stress response mechanisms and regulation of replicative lifespan (RLS) in yeast . YPK9 maintains mitochondrial membrane potential and function, with deficiencies leading to increased intracellular reactive oxygen species (ROS) levels and premature apoptosis. Using YPK9 antibodies in immunolocalization studies can help confirm its predominant vacuolar membrane localization while potentially revealing dynamic redistribution under stress conditions.

How does YPK9 relate to human ATP13A2 and what is its relevance to Parkinson's disease research?

YPK9 shares approximately 38% sequence identity with human ATP13A2, making it a valuable model for studying the function of this clinically significant protein . Human ATP13A2 encodes a multispanning membrane protein localized to lysosomes that functions as a polyamine transporter, exporting these organic polycations to the cytosol . Mutations in ATP13A2 are directly associated with Kufor-Rakeb syndrome, an early-onset form of Parkinson's disease . The homology between YPK9 and ATP13A2 allows researchers to use yeast as a model system to investigate fundamental mechanisms of polyamine transport, oxidative stress response, and protein condensate regulation that may be dysregulated in Parkinson's disease. When working with YPK9 antibodies, researchers should consider cross-reactivity studies against human ATP13A2 to establish evolutionary conservation of specific epitopes, which could strengthen translational research implications.

What are the key phenotypic changes observed in YPK9-deficient yeast cells?

YPK9-deficient yeast strains exhibit several distinct phenotypic alterations compared to wild-type cells:

• Increased sensitivity to oxidative stress, particularly hydrogen peroxide exposure

• Elevated intracellular reactive oxygen species (ROS) levels

• Decreased mitochondrial membrane potential

• Abnormal mitochondrial function

• Increased incidence of early apoptosis

• Shortened replicative lifespan (RLS)

Importantly, these phenotypic abnormalities can be reversed through overexpression of the catalase-encoding gene CTA1, indicating that the primary mechanism of YPK9 deficiency effects is through dysregulation of oxidative stress responses . For antibody-based validation of these phenotypes, researchers should employ multiple detection methods (western blotting, immunofluorescence, and flow cytometry) to correlate protein expression levels with observed phenotypic changes.

How can YPK9 antibodies be used to study oxidative stress responses in yeast models?

YPK9 antibodies can be employed in multiple experimental approaches to investigate oxidative stress responses:

• Protein Expression Quantification: Western blot analysis using YPK9 antibodies can track changes in expression levels following exposure to oxidative stressors like hydrogen peroxide. Experimental design should include time-course measurements (0, 15, 30, 60, 120 minutes post-exposure) at varying hydrogen peroxide concentrations (typically 50μM to 5mM) .

• Subcellular Localization Studies: Immunofluorescence microscopy with YPK9 antibodies can determine whether oxidative stress induces changes in protein localization. Co-staining with vacuolar and mitochondrial markers is essential to track potential redistribution under stress conditions.

• Protein-Protein Interaction Analysis: Co-immunoprecipitation using YPK9 antibodies can identify stress-dependent interaction partners, particularly focusing on potential associations with WHI2 and components of stress response pathways .

• Post-translational Modification Detection: Phosphorylation-specific antibodies against YPK9 can reveal whether oxidative stress alters the post-translational modification state of the protein, potentially affecting its activity.

For all these applications, researchers should validate antibody specificity using YPK9 deletion strains as negative controls to ensure signal specificity.

What methodological approaches are recommended for investigating YPK9-WHI2 genetic interactions using antibody-based techniques?

The negative genetic interaction between YPK9 and WHI2 during oxidative stress response can be investigated using several antibody-based approaches:

• Dual Immunofluorescence: Using antibodies against both YPK9 and WHI2 in wild-type, single mutant, and double mutant strains to visualize potential co-localization or changes in spatial distribution patterns.

• Sequential Immunoprecipitation: Performing tandem immunoprecipitation experiments to determine whether YPK9 and WHI2 exist in the same protein complex under normal or stress conditions.

• Chromatin Immunoprecipitation (ChIP): If either protein has potential DNA-binding activity or associates with transcription factors, ChIP assays using specific antibodies can identify target genes regulated by this interaction.

• Proximity Ligation Assays (PLA): For detecting close physical associations between YPK9 and WHI2 proteins in situ with single-molecule resolution.

Researchers should design experiments comparing four genetic backgrounds: wild-type (WHI2+/YPK9+), YPK9 deletion (WHI2+/ypk9Δ), WHI2 truncation (WHI2 G1324T/YPK9+), and double mutant (WHI2 G1324T/ypk9Δ) . The genetic interaction strength (ε) can be calculated using the multiplicative model as demonstrated in the literature, where a negative ε value signifies a negative genetic interaction .

What controls are essential when using YPK9 antibodies in co-localization studies with mitochondrial markers?

When conducting co-localization studies between YPK9 and mitochondrial markers, several critical controls must be implemented:

• Specificity Controls:

  • YPK9 deletion strain (ypk9Δ) to confirm antibody specificity

  • Peptide competition assay where the antibody is pre-incubated with excess immunizing peptide

  • Secondary antibody-only controls to assess background fluorescence

• Cross-talk Controls:

  • Single-label controls for each fluorophore to establish bleed-through parameters

  • Sequential acquisition of channels rather than simultaneous collection

  • Spectral unmixing for closely overlapping fluorophores

• Biological Controls:

  • Comparing normal conditions to oxidative stress, where mitochondrial dysfunction is expected in YPK9-deficient cells

  • Including strains overexpressing CTA1, which reverses YPK9 deficiency phenotypes

  • Treatment with mitochondrial uncouplers to validate mitochondrial membrane potential measurements

• Quantitative Assessment:

  • Employing Pearson's correlation coefficient and Manders' overlap coefficient for rigorous quantification

  • Z-stack acquisition and 3D reconstruction to avoid false co-localization interpretations

  • Analysis of multiple cells (n>30) across independent experiments (n≥3)

These controls ensure that any observed associations between YPK9 and mitochondrial components represent genuine biological interactions rather than technical artifacts.

How can researchers differentiate between direct and indirect effects when studying YPK9 function through antibody labeling?

Differentiating between direct and indirect effects of YPK9 on cellular processes requires multi-layered experimental approaches:

• Temporal Resolution Studies: Using synchronized cell populations and time-course antibody labeling to establish the sequence of events following YPK9 perturbation. Primary effects should precede secondary consequences.

• Rescue Experiments: Introduction of wild-type YPK9 versus mutant variants (ATPase-inactive, localization-altered) to determine which domains are critical for rescuing specific phenotypes.

• Domain-Specific Antibodies: Utilizing multiple antibodies recognizing different epitopes of YPK9 to map functional domains associated with specific cellular processes.

• Proximity-Dependent Labeling: Employing BioID or APEX2 fusions with YPK9 to identify proteins in its immediate vicinity, distinguishing direct interactors from downstream effectors.

• Conditional Expression Systems: Using tetracycline-inducible or galactose-inducible YPK9 expression to monitor immediate versus delayed consequences of protein restoration.

For distinguishing primary mitochondrial effects from secondary consequences, researchers should measure mitochondrial membrane potential changes immediately following acute YPK9 inhibition (using conditional systems) versus prolonged deficiency states .

How should researchers design experiments to investigate the role of YPK9 in polyamine transport using antibody-based approaches?

Based on YPK9's homology to human ATP13A2, which functions as a polyamine transporter , researchers can design the following antibody-based experiments:

• Polyamine-Dependent Localization: Immunofluorescence studies using YPK9 antibodies under varying polyamine concentrations (spermine, spermidine, putrescine) to detect potential redistribution.

• Proximity Labeling in Transporter Studies: YPK9 fused to proximity labeling enzymes (BioID, APEX2) followed by streptavidin pulldown and mass spectrometry to identify polyamine-dependent interaction partners.

• Conformational Antibodies: Development of conformation-specific antibodies that recognize YPK9 in polyamine-bound versus unbound states.

• Vacuolar Transport Assays: Correlating antibody-detected YPK9 levels with fluorescently labeled polyamine transport into vacuoles.

• Cross-linking Immunoprecipitation: Using membrane-permeable crosslinkers followed by YPK9 immunoprecipitation to capture transient polyamine-protein interactions.

Researchers should compare results in normal conditions versus polyamine-depleted media (achieved through addition of DFMO, an ornithine decarboxylase inhibitor) and include both wild-type YPK9 and human ATP13A2 expressed in yeast for comparative analyses.

What considerations should be made when designing time-course experiments to monitor YPK9 expression during oxidative stress?

Time-course experiments monitoring YPK9 expression during oxidative stress require careful planning:

• Optimal Sampling Intervals:

  • Immediate early response: 5, 15, 30 minutes post-stress

  • Early response: 1, 2, 4 hours post-stress

  • Adaptive response: 8, 12, 24 hours post-stress

• Stress Dosage Optimization:

  • Establish dose-response curves with hydrogen peroxide (25-200μM range) to determine sublethal concentrations

  • Include both acute (single high dose) and chronic (repeated low dose) exposure protocols

• Extraction Methodology:

  • Employ rapid cell harvesting techniques (filtration rather than centrifugation) to minimize processing artifacts

  • Use phosphatase and protease inhibitors in lysis buffers to preserve post-translational modifications

  • Consider separate fractionation protocols for membrane-bound versus cytosolic YPK9 pools

• Detection Approaches:

  • Western blotting with phosphorylation-specific antibodies to track activity changes

  • Flow cytometry for single-cell resolution of expression heterogeneity

  • Live-cell imaging with GFP-tagged YPK9 complemented by fixed-cell antibody validation

• Genetic Background Considerations:

  • Include WHI2 wild-type and mutant backgrounds due to the negative genetic interaction with YPK9

  • Compare BY4741 and BY4742 strain backgrounds which may respond differently to hydrogen peroxide

For this experimental design, researchers should adopt the standardized 50μM hydrogen peroxide exposure protocol used in previous studies to facilitate comparison with existing literature .

How can conflicting data regarding YPK9 localization be resolved when using different antibody clones?

Conflicting localization data from different YPK9 antibody clones may arise from several factors that require systematic resolution:

• Epitope Mapping and Accessibility:

  • Determine epitope locations for each antibody clone

  • Consider whether certain epitopes might be masked in specific subcellular compartments

  • Test accessibility through detergent titration studies during sample preparation

• Validation with Tagged Constructs:

  • Compare antibody staining patterns with GFP/RFP-tagged YPK9 expressed at endogenous levels

  • Confirm tagged construct functionality through complementation of ypk9Δ phenotypes

• Fixation and Permeabilization Optimization:

  • Systematically test multiple fixation methods (paraformaldehyde, methanol, glutaraldehyde)

  • Evaluate different permeabilization protocols (Triton X-100, saponin, digitonin) which may selectively preserve certain membranes

• Physiological State Standardization:

  • Control for cell cycle stage using synchronized populations

  • Standardize growth conditions including media composition and growth phase

  • Account for potential redistribution under various stress conditions

• Super-resolution Microscopy:

  • Apply techniques like STED, PALM, or STORM to resolve closely associated structures that might be indistinguishable in conventional microscopy

When facing discordant results, researchers should establish a consensus localization pattern based on concordance between multiple detection methods, prioritizing antibodies with validated specificity in knockout controls.

What approaches can help distinguish between YPK9 and other P5-type ATPases in antibody-based detection methods?

Distinguishing YPK9 from other P5-type ATPases, particularly Spf1p to which it shows similarity , requires:

• Epitope Selection Strategy:

  • Generate antibodies against unique, non-conserved regions identified through sequence alignment

  • Target N- or C-terminal domains that typically show greater divergence than catalytic domains

  • Validate epitope uniqueness through comprehensive BLAST analysis

• Cross-Reactivity Testing:

  • Systematic testing against cell lysates from strains with individual ATPase gene deletions

  • Heterologous expression of individual P5-ATPases for specificity verification

  • Peptide array screening to map precise epitope recognition profiles

• Competition Assays:

  • Pre-incubate antibodies with recombinant fragments of various P5-ATPases

  • Perform sequential depletion with related proteins before probing for YPK9

• Genetic Verification:

  • Correlate signal reduction with targeted depletion approaches (CRISPR, RNAi)

  • Use strains with epitope-tagged versions of each P5-ATPase for parallel detection

• Double-Labeling Strategies:

  • Employ dual immunofluorescence with antibodies against YPK9 and other P5-ATPases

  • Analyze co-localization patterns to identify unique versus overlapping distribution

For maximum specificity in complex applications like proteomics, researchers should consider immunoprecipitation with multiple antibodies targeting different epitopes of YPK9, followed by mass spectrometry confirmation.

How should researchers interpret changes in YPK9 expression levels in response to various stressors?

Interpreting changes in YPK9 expression requires consideration of multiple factors:

• Expression Versus Activity Distinction:

  • Protein abundance changes (detected by standard antibodies) may not correlate with functional activity

  • Complement expression studies with ATPase activity assays or phosphorylation status detection

  • Consider post-translational modifications that might alter protein function without changing levels

• Compensatory Mechanisms:

  • Assess expression of related P5-ATPases that might compensate for YPK9 alterations

  • Monitor expression of stress response genes like CTA1, which can reverse ypk9Δ phenotypes

  • Evaluate WHI2 status, as it shows negative genetic interaction with YPK9 under oxidative stress

• Strain Background Considerations:

  • Account for potential genetic background effects, particularly WHI2 status (full-length vs. truncated)

  • Compare responses between BY4741 and BY4742 backgrounds which may exhibit different hydrogen peroxide sensitivities

• Threshold Effects:

  • Determine whether expression changes correlate linearly with phenotypic outcomes

  • Identify potential threshold levels below which phenotypic effects become apparent

• Temporal Dynamics:

  • Distinguish between acute versus chronic adaptation responses

  • Consider biphasic responses where initial upregulation might be followed by downregulation

The following table summarizes expected YPK9 expression patterns under different experimental conditions:

This framework helps researchers contextualize YPK9 expression data within the broader cellular response to oxidative stress.

What are the optimal fixation and permeabilization protocols for YPK9 antibody staining in yeast cells?

Optimizing fixation and permeabilization for YPK9 antibody staining requires balancing epitope preservation with cellular access:

• Recommended Fixation Protocol:

  • 3.7% formaldehyde for 30 minutes at room temperature

  • Alternatively, 100% methanol for 6 minutes at -20°C for certain epitopes

  • Gentle fixation preserves membrane structure where YPK9 resides

• Cell Wall Digestion:

  • Zymolyase treatment (1 mg/ml for 30 minutes at 30°C)

  • Optimization of digestion time is critical to prevent over-digestion

  • Monitor spheroplast formation microscopically (>80% conversion recommended)

• Permeabilization Options:

  • For general access: 0.1% Triton X-100 for 5 minutes

  • For selective membrane permeabilization: 0.01% digitonin for 2 minutes

  • For vacuolar membrane preservation: 0.05% saponin for 10 minutes

• Blocking Considerations:

  • 3% BSA with 0.1% Tween-20 for 30 minutes

  • Addition of 5% normal serum matching secondary antibody host

  • Potential inclusion of polyamines (1mM spermidine) may preserve certain conformations

• Antibody Incubation:

  • Primary antibody at optimized dilution (typically 1:100-1:500) overnight at 4°C

  • Multiple wash steps (minimum 3×5 minutes) with PBS containing 0.1% Tween-20

  • Secondary antibody incubation for 1 hour at room temperature

For co-localization with mitochondrial markers, researchers should prefer mild non-denaturing fixation methods to preserve both protein epitopes and mitochondrial morphology, which is particularly important given YPK9's effects on mitochondrial function .

What troubleshooting approaches are recommended when YPK9 antibodies show inconsistent results across experiments?

When facing inconsistent YPK9 antibody results, researchers should implement a systematic troubleshooting framework:

• Antibody Storage and Handling:

  • Verify proper storage conditions (temperature, avoid freeze-thaw cycles)

  • Prepare single-use aliquots to prevent repeated freeze-thaw cycles

  • Check for antibody precipitation or contamination

• Sample Preparation Consistency:

  • Standardize cell density and growth phase at harvest

  • Ensure consistent lysis conditions (buffer composition, inhibitor cocktails)

  • Monitor protein degradation with additional housekeeping antibodies

• Technical Variables:

  • Test multiple antibody lots and request validation data from manufacturers

  • Optimize antibody concentration through titration experiments

  • Evaluate different blocking agents to reduce background

• Biological Variability:

  • Confirm strain genotype, particularly WHI2 status which affects hydrogen peroxide sensitivity

  • Control for cell stress during cultivation and harvesting

  • Consider inherited epigenetic states or suppressor mutations

• Quantification Methods:

  • Implement internal loading controls for western blots

  • Use automated image analysis software to reduce subjective interpretation

  • Consider technical replicates within experiments and biological replicates across independent cultures

For particularly challenging applications, researchers might need to develop new monoclonal antibodies with higher specificity or consider alternative detection strategies such as epitope tagging of endogenous YPK9.

How does YPK9 research in yeast inform our understanding of neurodegenerative disease mechanisms?

YPK9 research in yeast provides several mechanistic insights relevant to neurodegenerative disease:

• Polyamine Metabolism Connection:

  • YPK9's homology to human ATP13A2 (a polyamine transporter) links polyamine homeostasis to Parkinson's disease

  • Polyamines function in RNA binding, ROS scavenging, and activation of eIF5A through hypusination

  • These processes represent potential therapeutic targets in neurodegeneration

• Oxidative Stress Mechanism:

  • YPK9 deficiency increases sensitivity to oxidative stress and ROS accumulation

  • Oxidative damage is a central mechanism in multiple neurodegenerative conditions

  • YPK9's role suggests conserved cellular defense mechanisms against oxidative damage

• Mitochondrial Connection:

  • YPK9-deficient yeast shows decreased mitochondrial membrane potential and function

  • Mitochondrial dysfunction is a hallmark of Parkinson's disease and other neurodegenerative disorders

  • This suggests ATP13A2 might similarly protect against mitochondrial impairment in neurons

• Genetic Interaction Networks:

  • The negative interaction between YPK9 and WHI2 during oxidative stress demonstrates how genetic background influences disease susceptibility

  • This parallels genetic modifier effects in human neurodegenerative diseases

  • The finding that WHI2 blocks TORC1 connects this pathway to nutrient sensing and protein synthesis regulation

• Therapeutic Implications:

  • The rescue of ypk9Δ phenotypes by CTA1 overexpression suggests antioxidant strategies might benefit ATP13A2-deficient patients

  • Targeting polyamine metabolism might represent a novel therapeutic approach for Parkinson's disease

Researchers using YPK9 antibodies in these contexts should consider parallel experiments with human ATP13A2 antibodies to validate conservation of mechanisms between yeast and human systems.

What are the recommended approaches for studying the evolutionary conservation of YPK9 function across species?

Investigating evolutionary conservation of YPK9 function requires multi-organism comparative approaches:

• Sequence-Based Analysis:

  • Phylogenetic tree construction of P5-type ATPases across species

  • Identification of conserved domains versus species-specific regions

  • Selection of conserved epitopes for generating cross-species reactive antibodies

• Cross-Species Functionality Tests:

  • Complementation assays expressing human ATP13A2 in ypk9Δ yeast

  • Assessment of whether human ATP13A2 rescues oxidative stress sensitivity

  • Evaluation of whether species-specific domains confer specialized functions

• Parallel Phenotyping:

  • Comparative analysis of phenotypes in yeast (ypk9Δ), worms (catp-6 mutants), flies (dATP13A2 mutants), and mammalian cell models

  • Standardized oxidative stress protocols across model systems

  • Antibody-based detection of subcellular localization across species

• Conservation of Interactions:

  • Investigation of whether YPK9-WHI2 interaction is conserved with human homologs

  • Cross-species immunoprecipitation studies to identify conserved interaction partners

  • Functional conservation testing of key regulatory pathways like TORC1 inhibition

• Domain Swap Experiments:

  • Creation of chimeric proteins with domains exchanged between yeast YPK9 and human ATP13A2

  • Antibody-based detection of chimeric protein localization and function

  • Identification of domains that confer species-specific versus universally conserved functions

This multi-level approach allows researchers to distinguish between core conserved functions of YPK9/ATP13A2 and species-specific adaptations, providing valuable insights for translational research.